| Brigatinib studied in …STUDIED_INderived34 of 34show fewer |
|---|
| → studied in | NCT04374305Phase 2 · recruiting Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) · 34 trials list this drug (10 active) | — | — | Meningioma,Vestibular Schwannoma,Ependymoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04227028Phase 1 · active not recruiting Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC · 34 trials list this drug (10 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04318938Phase 2 · completed Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06813079Phase 2 · recruiting Using Tumor Models to Determine Treatments · 34 trials list this drug (10 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737994Phase 2 · terminated Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer · 34 trials list this drug (10 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05100069recruiting Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05721950active not recruiting A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04223596Phase 2 · active not recruiting Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients · 34 trials list this drug (10 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04925609Phase 1/Phase 2 · recruiting Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors · 34 trials list this drug (10 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive,Inflammatory Myofibroblastic Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05200481Phase 2 · active not recruiting Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03707938Phase 1 · active not recruiting Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer · 34 trials list this drug (10 active) | — | — | Lung Carcinoma,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03596866Phase 3 · completed A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer · 34 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03535740Phase 2 · completed A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib · 34 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06522360Phase 2 · withdrawn Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834348completed A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05718297Phase 2 · withdrawn Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532149recruiting ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03546894completed A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03410108Phase 2 · completed Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) · 34 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 34 trials list this drug (10 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04074993Phase 2 · unknown Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04647110completed Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. · 34 trials list this drug (10 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03420742Phase 1 · completed A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors · 34 trials list this drug (10 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02706626Phase 2 · terminated Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04634110Phase 2 · terminated Brigatinib Before Brain Irradiation Trial (B3i Trial) · 34 trials list this drug (10 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04005144Phase 1 · terminated Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer · 34 trials list this drug (10 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05361564Phase 2 · unknown A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions. · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03868423Phase 2 · withdrawn Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers · 34 trials list this drug (10 active) | — | — | Malignant Neoplasm,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02737501Phase 3 · completed ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants · 34 trials list this drug (10 active) | — | — | Carcinoma,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01449461Phase 1/Phase 2 · completed A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) · 34 trials list this drug (10 active) | — | — | Lymphoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02094573Phase 2 · completed A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib · 34 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03719898Phase 2 · withdrawn Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma · 34 trials list this drug (10 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04260009Phase 1/Phase 2 · withdrawn Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors · 34 trials list this drug (10 active) | — | — | Solid Neoplasm,Inflammatory Myofibroblastic Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02784158no longer available An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer · 34 trials list this drug (10 active) | — | — | Carcinoma,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |